Peyrin J C, Waldmann V, Girardet P, Pouzol P, Duret J, Fargnoli J M, Magne J L, Perron Y
J Chir (Paris). 1986 Jun-Jul;123(6-7):417-23.
Consumption coagulopathy (CIVD) is a frequent complication of peritoneojugular bypass operation. Preventive treatment applied involves low-dose heparin (1.5 mg/kg/d) to maintain an antithrombin III concentration of at least 65%. Results are evaluated in 6 patients treated by 7 bypass operations. A biologic CIVD developed in 2 cases (29%) but no clinical coagulopathy was observed. This incidence is less than that usually reported, a literature review indicating a biologic coagulopathy in 65% of cases, with clinical evidence in 12.5%. Furthermore, patients with spontaneously elevated AT III levels did not develop CIVD while, in contrast, sufficiently high concentrations of AT III could not be maintained in the 2 patients with coagulopathy. These findings suggest the interest of prevention of a CIVD by the use of this procedure.
消耗性凝血病（CIVD）是颈静脉腹膜分流术常见的并发症。预防性治疗采用小剂量肝素（1.5毫克/千克/天），以维持抗凝血酶III浓度至少为65%。对7例分流手术治疗的6例患者的结果进行了评估。2例（29%）发生了生物学CIVD，但未观察到临床凝血病。该发病率低于通常报道的发病率，文献综述表明，65%的病例存在生物学凝血病，12.5%有临床证据。此外，抗凝血酶III水平自发升高的患者未发生CIVD，相反，2例凝血病患者无法维持足够高的抗凝血酶III浓度。这些发现表明采用该方法预防CIVD是有意义的。
